Alnylam Pharmaceuticals
Reports summarize new developments from Alnylam Pharmaceuticals
Published in Lab Law Weekly, January 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Alnylam Pharmaceuticals.
Report 1: Alnylam Pharmaceuticals, Inc., (ALNY) has initiated a human experimental infection study with respiratory syncytial virus (RSV) designed to establish a safe and reliable RSV infection of the upper respiratory tract in adult volunteers.
Upon determination of the optimal level of RSV inoculum, Alnylam plans to initiate a subsequent clinical protocol to evaluate the anti-viral activity for ALN-RSV01, an RNAi therapeutic being developed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2007-01-19)
More Articles from Lab Law Weekly
- Awards
Neuropharma receives Frost & Sullivan International Excellence in Technology award - Business & Finance
Genmab discloses details of the issue of shares to GlaxoSmithKline - Business Update
Advancis closes private placement of common equity, files application for Pulsys - Business Update
Analytical Spectral Devices launches portable drug anti-counterfeiting technology - Business Update
Anchen announces approval of generic version of Wellbutrin XL - Business Update
Mergers and acquisitions firm MidMarket Capital advises Van Slyck on sale to Eclipsys - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
